Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen Tumor Vaccine in Post-Op Stage IIIA Lung Cancer
NCT03807102Phase 2Not yet recruiting
- Sponsor
- Yongchang Zhang
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Personalized Neoantigen Tumor Vaccine (Yongchang Zhang) in lung adenocarcinoma, sponsored by Yongchang Zhang. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
Personalized Neoantigen Tumor Vaccine (Yongchang Zhang)
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03807102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807102.